Optimizing NK Cell-Engaging Bispecific Antibody Therapy Targeting CD33

$83,621R21FY2021CANIH

Fred Hutchinson Cancer Center, Seattle WA

Investigators

Roland Bruno Waltercontact

View original record on NIH RePORTER →